Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

Pages

4210 items
12:00 AM, Oct 31, 2016  |  BC Extra | Top Story

Third Rock closes fourth fund at $616M

Third Rock Ventures closed its Fund IV at $616 million, exceeding its $600 million target. The firm intends to launch or invest in 10-12 early stage companies focused on oncology, immunology, neurology, cardiovascular disease and...
12:00 AM, Oct 28, 2016  |  BC Extra | Top Story

Pricing woes pummel biopharma stocks

Biopharmas suffered sell-offs on Friday as investors digested concerns about drug pricing that affected the outlook for Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Amgen Inc. (NASDAQ:AMGN) and AbbVie Inc. (NYSE:ABBV). Novo lost more than $13 billion...
12:00 AM, Oct 27, 2016  |  BC Extra | Top Story

BMS rises on earnings, promise of cost containment

Along with reporting 3Q16 earnings that beat estimates and raising full-year guidance, Bristol-Myers Squibb Co. (NYSE:BMY) on Thursday announced it would keep non-GAAP operating expenses "roughly flat" in 2016-20, even as it increases R&D spending...
12:00 AM, Oct 26, 2016  |  BC Extra | Top Story

Biogen reports Tecfidera growth, ends S1P program

In its 3Q16 earnings report, Biogen Inc. (NASDAQ:BIIB) said sales of multiple sclerosis drug Tecfidera dimethyl fumarate grew 10% compared to 3Q15. The company also said it discontinued development of autoimmune candidate amiselimod ( MT-1303),...
12:00 AM, Oct 25, 2016  |  BC Extra | Top Story

Novartis says CAR T on track

Novartis AG (NYSE:NVS; SIX:NOVN) on Tuesday said it remains on track to submit a BLA to FDA early next year for its CTL019 chimeric antigen receptor (CAR) T cell therapy to treat pediatric acute lymphoblastic...
12:00 AM, Oct 24, 2016  |  BC Extra | Top Story

FDA approves Keytruda as first-line NSCLC therapy

Merck & Co. Inc. (NYSE:MRK) said late Monday FDA approved Keytruda pembrolizumab as a first-line treatment for metastatic non-small lung cancer patients with ≥50% PD-L1 expression and with no EGFR or anaplastic lymphoma kinase (ALK)...
12:00 AM, Oct 21, 2016  |  BC Extra | Top Story

Keytruda passes Phase III bladder cancer test

Merck & Co. Inc. (NYSE:MRK) said PD-1 mAb Keytruda pembrolizumab met the co-primary overall survival (OS) endpoint in the Phase III KEYNOTE-045 trial to treat bladder cancer. The pharma stopped the study early on the...
12:00 AM, Oct 20, 2016  |  BC Extra | Top Story

Alkermes rises after MDD therapy passes Phase III test

Alkermes plc (NASDAQ:ALKS) gained $19.47 (45%) to $62.98 in early after-hours trading Thursday after it said the higher of two doses of ALKS 5461 met the primary endpoint of the FORWARD-5 trial as an adjunctive...
12:00 AM, Oct 19, 2016  |  BC Extra | Top Story

FDA approves Lilly's Lartruvo for STS

FDA granted accelerated approval to Lartruvo olaratumab from Eli Lilly and Co. (NYSE:LLY) in combination with doxorubicin to treat advanced soft tissue sarcoma patients who cannot be cured with radiation or surgery and for whom...
12:00 AM, Oct 18, 2016  |  BC Extra | Top Story

LLS launches collaborative AML trial

On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia. The trial will enroll newly diagnosed AML patients aged...

Pages